Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Austin, Texas 78759


Purpose:

The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.


Criteria:

Inclusion Criteria: - No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Exclusion Criteria: - Participation in a clinical trial within 30 days prior to study initiation. - Positive blood screen for HIV or Hepatitis B and C. - History of allergic or adverse responses to zidovudine.


NCT ID:

NCT00601562


Primary Contact:

Principal Investigator
Daniel V Freeland, DO
CEDRA Clinical Research


Backup Contact:

N/A


Location Contact:

Austin, Texas 78759
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.